$ cat ./records/gates-foundation-awards-32-6-million-to-duke-university-to-lead-h-2013.txt
Gates Foundation Awards $32.6 Million to Duke University to Lead HIV Antibody Monitoring Consortium for Global Vaccine Trials
[RECORD.TXT] · cat --full
The Gates Foundation's Collaboration for AIDS Vaccine Discovery awarded a five-year $32.6 million grant to Duke University's David Montefiori to lead the Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC), providing standardised testing of antibody breadth, potency, and neutralisation for HIV vaccine candidates across the global clinical pipeline. CAVIMC enables rigorous cross-trial comparison of HIV vaccine strategies and is essential infrastructure for the CAVD network spanning IAVI, Scripps Research, and Fred Hutchinson Cancer Center.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Awards $9.6 Million to One Acre Fund for Agroforestry Integration Across East Africa
Next →
Gates Foundation Awards $10 Million to CDC Foundation to Establish MenAfriNet Meningitis Belt Surveillance
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.